Literature DB >> 22684763

Effect of hemodialysis session on the dynamics of carnitine ester profile changes in L-carnitine pretreated end-stage renal disease patients.

Botond Csiky1, Judit Bene, Istvan Wittmann, Endre Sulyok, Bela Melegh.   

Abstract

PURPOSE: Carnitine deficiency is common in end-stage renal disease (ESRD) patients receiving hemodialysis (HD) treatment. We investigated the effects of L-carnitine supplementation on acyl carnitine (AC) profile and the changes of distinct ACs during a single HD session in long-term L-carnitine pretreated ESRD patients.
METHODS: Twenty non-diabetic adult patients and 37 healthy controls were studied. Blood samples were drawn before and after 12 weeks of carnitine supplementation, then hourly during an HD session, as well as 30 min after the end of the session. Free and individual AC plasma levels were determined by using ESI MS/MS technique.
RESULTS: HD patients showed lower free- and total carnitine levels and elevated ACs and acyl/free carnitine ratio before carnitine supplementation. The L-carnitine supplementation resulted in dramatic elevation of all carnitine esters. The HD session induced a progressive decline in free, short-chain, and dicarboxylic ACs (~80 % of pre-HD amount was washed out); the decrease of medium-chain ACs proved to be more moderate (~60 % washed out), whereas the long-chain ACs remained unaffected. Already 30 min after HD, a substantial increase was seen in free carnitine concentration (reaching 26 % of predialysis level) and the ACs also started to replenish (to 21-52 % of predialysis levels), without further exogenous carnitine load.
CONCLUSIONS: The washout induced by HD session results in variable depletion of short-, medium-, and long-chain carnitine esters in carnitine-pretreated patients; the recovery of the circulating carnitine esters from the body stores occurs within 30 min after the cessation of the HD procedure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684763     DOI: 10.1007/s11255-012-0209-x

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  40 in total

Review 1.  Carnitine replacement in end-stage renal disease and hemodialysis.

Authors:  Menotti Calvani; Paola Benatti; Angelo Mancinelli; Stefania D'Iddio; Vincenzo Giordano; Aleardo Koverech; Antonino Amato; Eric P Brass
Journal:  Ann N Y Acad Sci       Date:  2004-11       Impact factor: 5.691

2.  Effects of L-carnitine administration on short-chain fatty acid (acetic acid) and long-chain fatty acid metabolism during hemodialysis.

Authors:  K Maeda; T Shinzato; H Kobayakawa
Journal:  Nephron       Date:  1989       Impact factor: 2.847

3.  Soluble Fas is a marker of coronary artery disease in patients with end-stage renal disease.

Authors:  M J Hébert; M Masse; N Vigneault; I Sirois; S Troyanov; F Madore
Journal:  Am J Kidney Dis       Date:  2001-12       Impact factor: 8.860

4.  Evaluation of the effect of intravenous L-carnitine therapy on function, structure and fatty acid metabolism of skeletal muscle in patients receiving chronic hemodialysis.

Authors:  G Siami; M E Clinton; R Mrak; J Griffis; W Stone
Journal:  Nephron       Date:  1991       Impact factor: 2.847

5.  Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients.

Authors:  Murat Duranay; Hatice Akay; Fatma Meriç Yilmaz; Mehmet Senes; Nurçin Tekeli; Dogan Yücel
Journal:  Nephrol Dial Transplant       Date:  2006-07-22       Impact factor: 5.992

6.  Quantitative assessment of carnitine loss during hemodialysis and hemofiltration.

Authors:  M Leschke; K W Rumpf; T Eisenhauer; C Fuchs; K Becker; U Köthe; F Scheler
Journal:  Kidney Int Suppl       Date:  1983-12       Impact factor: 10.545

7.  Carnitine-dependent changes of metabolic fuel consumption during long-term treatment with valproic acid.

Authors:  B Melegh; M Pap; E Morava; D Molnar; M Dani; J Kurucz
Journal:  J Pediatr       Date:  1994-08       Impact factor: 4.406

Review 8.  Dialysis-related carnitine disorder and levocarnitine pharmacology.

Authors:  Allan Evans
Journal:  Am J Kidney Dis       Date:  2003-04       Impact factor: 8.860

9.  Red blood cells and platelet membrane fatty acids in non-dialyzed and dialyzed uremics.

Authors:  D Girelli; M Azzini; O Olivieri; P Guarini; M T Trevisan; A Lupo; P Bernich; G Panzetta; R Corrocher
Journal:  Clin Chim Acta       Date:  1992-10-30       Impact factor: 3.786

Review 10.  Pharmacokinetic considerations for the therapeutic use of carnitine in hemodialysis patients.

Authors:  E P Brass
Journal:  Clin Ther       Date:  1995 Mar-Apr       Impact factor: 3.393

View more
  4 in total

Review 1.  Inflammation and L-carnitine therapy in hemodialysis patients: a review.

Authors:  Saman Khalatbari-Soltani; Hadi Tabibi
Journal:  Clin Exp Nephrol       Date:  2014-12-02       Impact factor: 2.801

2.  L-Carnitine status in end-stage renal disease patients on automated peritoneal dialysis.

Authors:  Lorenzo Di Liberato; Arduino Arduini; Claudia Rossi; Augusto Di Castelnuovo; Cosima Posari; Paolo Sacchetta; Andrea Urbani; Mario Bonomini
Journal:  J Nephrol       Date:  2014-03-06       Impact factor: 3.902

Review 3.  Mass Spectrometric Analysis of L-carnitine and its Esters: Potential Biomarkers of Disturbances in Carnitine Homeostasis.

Authors:  Judit Bene; Andras Szabo; Katalin Komlósi; Bela Melegh
Journal:  Curr Mol Med       Date:  2020       Impact factor: 2.222

4.  Exploration of anti-inflammatory mechanism of forsythiaside A and forsythiaside B in CuSO4-induced inflammation in zebrafish by metabolomic and proteomic analyses.

Authors:  Lihong Gong; Linyuan Yu; Xiaohong Gong; Cheng Wang; Naihua Hu; Xuyang Dai; Cheng Peng; Yunxia Li
Journal:  J Neuroinflammation       Date:  2020-06-03       Impact factor: 8.322

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.